Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis

mRNA-based SARS-CoV-2 vaccines offer a preventive strategy against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections that is of interest in the care of patients on hemodialysis (HDP). We measured humoral immune responses in 72 HDP after standard vaccination with two doses of th...

Full description

Bibliographic Details
Main Authors: Michael Jahn, Johannes Korth, Oliver Dorsch, Olympia Evdoxia Anastasiou, Burkhard Sorge-Hädicke, Bartosz Tyczynski, Anja Gäckler, Oliver Witzke, Ulf Dittmer, Sebastian Dolff, Benjamin Wilde, Andreas Kribben
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Vaccines
Subjects:
SARS-CoV-2
mRNA-vaccines
hemodialysis
chronic kidney disease
COVID-19
antibody titers
Online Access:https://www.mdpi.com/2076-393X/9/4/360

Internet

https://www.mdpi.com/2076-393X/9/4/360

Similar Items